Regentis Biomaterials Ltd. (RGNT) - Net Assets
Based on the latest financial reports, Regentis Biomaterials Ltd. (RGNT) has net assets worth $4.74 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.62 Million) and total liabilities ($2.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See RGNT equity to assets ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.74 Million |
| % of Total Assets | 62.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Regentis Biomaterials Ltd. - Net Assets Trend (2022–2025)
This chart illustrates how Regentis Biomaterials Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore RGNT net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Net Assets for Regentis Biomaterials Ltd. (2022–2025)
The table below shows the annual net assets of Regentis Biomaterials Ltd. from 2022 to 2025. For live market cap and overall valuation, see RGNT market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.74 Million | +111.54% |
| 2024-12-31 | $-41.10 Million | +10.46% |
| 2023-12-31 | $-45.91 Million | -9.14% |
| 2022-12-31 | $-42.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regentis Biomaterials Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1297900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $60.54 Million | 1276.10% |
| Total Equity | $4.74 Million | 100.00% |
Regentis Biomaterials Ltd. Competitors by Market Cap
The table below lists competitors of Regentis Biomaterials Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Indonesian Tobacco Tbk PT
JK:ITIC
|
$11.24 Million |
|
FingerMotion Inc
NASDAQ:FNGR
|
$11.25 Million |
|
Dycasa SA
BA:DYCA
|
$11.25 Million |
|
Dare Bioscience Inc
NASDAQ:DARE
|
$11.26 Million |
|
Kiora Pharmaceuticals Inc
NASDAQ:KPRX
|
$11.24 Million |
|
Sirona Biochem Corp
V:SBM
|
$11.23 Million |
|
InnSuites Hospitality Trust
NYSE MKT:IHT
|
$11.23 Million |
|
Tier One Silver Inc
V:TSLV
|
$11.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regentis Biomaterials Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -41,104,000 to 4,744,000, a change of 45,848,000.
- Net loss of 13,648,000 reduced equity.
- New share issuances of 8,224,000 increased equity.
- Other factors increased equity by 51,272,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.65 Million | -287.69% |
| Share Issuances | $8.22 Million | +173.36% |
| Other Changes | $51.27 Million | +1080.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Regentis Biomaterials Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-8.53 | $1.60 | x |
| 2023-12-31 | $-9.31 | $1.60 | x |
| 2024-12-31 | $-7.94 | $1.60 | x |
| 2025-12-31 | $0.92 | $1.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regentis Biomaterials Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -287.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.61x
- Recent ROE (-287.69%) is below the historical average (-71.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $2.76 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $458.50K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $8.91 Million |
| 2025 | -287.69% | 0.00% | 0.00x | 1.61x | $-14.12 Million |
Industry Comparison
This section compares Regentis Biomaterials Ltd.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,850,322,670
- Average return on equity (ROE) among peers: -22.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regentis Biomaterials Ltd. (RGNT) | $4.74 Million | 0.00% | 0.61x | $11.24 Million |
| Akoya Biosciences Inc (AKYA) | $18.57 Million | -89.96% | 3.18x | $64.44 Million |
| Align Technology Inc (ALGN) | $490.78 Million | 13.59% | 0.32x | $10.22 Billion |
| AngioDynamics Inc (ANGO) | $372.19 Million | 2.67% | 0.10x | $476.15 Million |
| AptarGroup Inc (ATR) | $1.98 Billion | 12.30% | 1.09x | $7.66 Billion |
| AtriCure Inc (ATRC) | $15.61 Million | -34.94% | 1.17x | $2.21 Billion |
| Avinger Inc (AVGR) | $13.08 Million | -151.60% | 1.54x | $1.52 Million |
| Avantor Inc (AVTR) | $5.25 Billion | 6.11% | 1.47x | $9.19 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.35 Billion |
| Baxter International Inc (BAX) | $9.12 Billion | 14.08% | 2.68x | $12.59 Billion |
| Becton Dickinson and Company (BDX) | $681.10 Million | 12.92% | 0.82x | $48.93 Billion |
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical tr… Read more